Free Trial
NASDAQ:ZIVO

ZIVO Bioscience (ZIVO) Stock Price, News & Analysis

ZIVO Bioscience logo
$6.50 -0.01 (-0.21%)
As of 10/16/2026 03:38 PM Eastern

About ZIVO Bioscience Stock (NASDAQ:ZIVO)

Advanced

Key Stats

Today's Range
$6.50
▼
$6.91
50-Day Range
$3.11
▼
$6.51
52-Week Range
$1.11
▼
$17.50
Volume
1,888 shs
Average Volume
2,770 shs
Market Capitalization
$27.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ZIVO Bioscience, Inc. is a biotechnology company focused on developing health and wellness products from proprietary algae cultures. Its research platform is designed to identify and produce bioactive compounds, including proteins, peptides, polysaccharides, lipids and other naturally occurring substances with potential nutritional, therapeutic and functional applications.

The company’s development programs address human health, animal health and aquaculture. Potential applications include immune-system support, inflammation management, metabolic health, animal nutrition and disease prevention. ZIVO has also pursued the development of algae-based ingredients and formulations that could be commercialized directly or through licensing, partnering and other strategic arrangements.

ZIVO Bioscience is based in the United States and has historically operated as a development-stage life sciences company, emphasizing research, product validation and commercial partnerships rather than a broad portfolio of established consumer products. The company was previously known as Health Enhancement Products, Inc. and later adopted the ZIVO Bioscience name as it focused more specifically on its algae-based biotechnology programs.

AI Generated. May Contain Errors.

Receive ZIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZIVO Stock News Headlines

Zivo Bioscience Inc. Wt
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
ZIVO Bioscience Provides Special Letter to Shareholders
See More Headlines

ZIVO Stock Analysis - Frequently Asked Questions

ZIVO Bioscience's stock was trading at $8.70 at the beginning of the year. Since then, ZIVO stock has decreased by 25.3% and is now trading at $6.50.

ZIVO Bioscience, Inc. (NASDAQ:ZIVO) released its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.06) earnings per share for the quarter. The biotechnology company had revenue of $0.02 million for the quarter.

ZIVO Bioscience's stock reverse split before market open on Friday, October 27th 2023.The 1-6 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Shares of ZIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIVO Bioscience investors own include NIO (NIO), Anglo American (AAL), American Airlines Group (AAL), Abeona Therapeutics (ABEO), Amarin (AMRN), Ares Capital (ARCC) and AST SpaceMobile (ASTS).

Company Calendar

Last Earnings
5/11/2020
Today
10/17/2026
Next Earnings (Estimated)
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ZIVO
Previous Symbol
OTCMKTS:HEPI
CIK
1101026
Fax
N/A
Employees
10
Year Founded
1999

Profitability

EPS (Trailing Twelve Months)
($1.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.78 million
Net Margins
N/A
Pretax Margin
-17,113.75%
Return on Equity
N/A
Return on Assets
-2,240.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.17
Quick Ratio
0.17

Sales & Book Value

Annual Sales
$15.85 thousand
Price / Sales
1,728.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.81) per share
Price / Book
-8.02

Miscellaneous

Outstanding Shares
4,215,000
Free Float
2,911,000
Market Cap
$27.40 million
Optionable
Not Optionable
Beta
0.38

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:ZIVO) was last updated on 10/16/2026 by MarketBeat.com Staff.
From Our Partners